Futures point higher; AMD reports; Novo to cut costs - what’s moving markets
Montgomery Alan Bruce, a director at Xencor Inc (NASDAQ:XNCR), recently sold shares of the company amounting to $20,422. The transaction, which took place on June 16, 2025, involved the sale of 2,215 shares at a price of $9.22 each. This sale was conducted under a 10b5-1 plan that Montgomery adopted on June 28, 2024. The sale comes amid a challenging period for Xencor, with the stock down over 63% in the past six months, though InvestingPro analysis suggests the stock is currently undervalued.
Earlier, on June 12, 2025, Montgomery acquired 13,686 shares of Xencor common stock, which were restricted stock units that will fully vest on the first anniversary of the grant date. Additionally, he was granted stock options for 27,372 shares, with an exercise price of $9.43 per share. These options will vest in equal monthly installments over the next year, becoming fully vested by June 12, 2026. According to InvestingPro data, while Xencor holds more cash than debt on its balance sheet, the company is quickly burning through cash. Get access to 8 more exclusive ProTips and comprehensive analysis in the Pro Research Report, available on InvestingPro.
In other recent news, Xencor, Inc. reported that its investigational anti-TL1A antibody, XmAb942, will advance into a Phase 2b study for ulcerative colitis patients, following positive interim results from a dose-escalation study. The trial is set to begin in the second half of 2025, with around 220 patients participating to evaluate the drug’s efficacy and safety. In related developments, JPMorgan analyst Brian Cheng adjusted Xencor’s stock price target to $20, down from $23, while maintaining an Overweight rating, citing the company’s focus on its immunological research portfolio. Cheng noted that Xencor’s first-quarter results met expectations, with significant attention on strategic execution moving forward.
Additionally, William Blair initiated coverage of Xencor with an Outperform rating, acknowledging the potential of the company’s pipeline to deliver distinctive clinical data in the next 6 to 12 months. The analysts highlighted the promising capabilities of Xencor’s XmAb platform, particularly in the development of T-cell engagers for cancer treatment. Xencor’s progress in this area is expected to produce unique clinical outcomes. The company’s financial position remains strong, supporting its ongoing clinical milestones. These recent developments underscore Xencor’s strategic advancements in its therapeutic programs and the confidence analysts have in its potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.